NEW YORK — Novartis Pharmaceuticals Corporation will reportedly pay $390 million to the federal government and 40-plus states to settle charges of paying specialty pharmacies illegal kickbacks.
Filed Under: Exjade News – Lawsuits, Settlements, Information
LONDON — Less than a year after paying $390 million to settle criminal cases brought under the False Claims Act, a whistleblower claims the maker of Exjade is doing much the same thing on the other side of the world. The Swiss drugmaker is investigating claims that the company paid nearly $300,000 to government officials in […]
Exjade (deferasirox) was approved through the FDA’s accelerated approval program in 2005 as a drug mean to treat chronic iron overload developed by multiple long-term blood transfusions.
Exjade (deferasirox) is an oral iron chelator approved by the FDA in 2005 to prevent chronic iron overload in patients that have been subjected to multiple long-term blood transfusions.
Exjade (deferasirox) is an FDA-approved orally administered iron chelator developed to combat chronic iron overload triggered by multiple long-term blood transfusions.
Approved by the U.S. Food and Drug Administration in 2005 to combat chronic iron overload, Exjade (deferasirox) is a unique drug holding an oral iron chelator classification.
Exjade (deferasirox) was approved in 2005 by the FDA as an oral iron chelator designed to treat chronic iron overload present in patients who suffered from beta-thalassemia and were subjected to multiple long-term blood transfusions.